UNSPSC 51383301: Lumiracoxib

This classification denotes a cyclooxygenase inhibitor with the molecular formula C15H13ClFNO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier V91T9204HU, chemically known as benzeneacetic acid, 2-((2-chloro-6-fluorophenyl)amino)-5-methyl- but generally known as lumiracoxib, which bears US NIH Compound Identifier 151166. European Medicines Agency schedules Lumiracoxib in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB21406.

UNSPSC 51383301 Lumiracoxib, a Commodity code, nominally designates a single nonsteroidal anti-inflammatory drug (NSAID). However, recent state and local opportunities tagged under this code show little direct activity around lumiracoxib itself; instead, the code appears to capture broader pharmaceutical procurement across multiple product categories, including naloxone, over-the-counter medications, and generic multi-source drugs. State and local health departments, cooperative purchasing alliances, and county health systems are the primary issuing bodies, seeking to establish supply relationships and pricing agreements for pharmaceutical products through a mix of IFBs, RFPs, and RFIs. The work involves competitive bidding for defined unit volumes, negotiation of pricing models, compliance with FDA manufacturing standards and Drug Supply Chain Security Act requirements, and fulfillment through authorized wholesaler networks or direct delivery to specified locations.

Recent activity spans Florida, Texas, and Minnesota. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with a July 26, 2023 response deadline and two-year initial term plus one-year renewal option. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, to gather vendor capabilities for a direct-to-manufacturer prescription program serving state employee health plans outside traditional pharmacy benefit manager channels. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued RFP S1070000015802 on January 20, 2026, for generic multi-source pharmaceuticals and OTC products across participating state and local jurisdictions, with a March 26, 2026 proposal deadline, awards effective July 1, 2026, and a two-year contract term. Vendors must maintain cGMP and DSCSA compliance, establish relationships with authorized wholesalers, and accept pricing models ranging from flat-fee to WAC-minus structures.